2026-06-01T03:40:19Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/166622026-02-03T10:53:26Zcom_10630_2254col_10630_37953

García-Caballero, Melissa Rodríguez-Quesada, Ana María Medina-Torres, Miguel Ángel Mari-Beffa, Manuel 2018-10-19T07:38:40Z 2018-10-19T07:38:40Z 2018-10-19 https://hdl.handle.net/10630/16662 10.1016/j.drudis.2017.10.018 Zebrafish, an amenable small teleost fish with a complex mammal-like circulatory system, is being increasingly used for drug screening and toxicity studies. It combines the biological complexity of in vivo models with a higher-throughput screening capability compared with other available animal models. Externally growing, transparent embryos, displaying well-defined blood and lymphatic vessels, allow the inexpensive, rapid, and automatable evaluation of drug candidates that are able to inhibit neovascularisation. Here, we briefly review zebrafish as a model for the screening of anti(lymph) angiogenic drugs, with emphasis on the advantages and limitations of the different zebrafish-based in vivo assays. eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Neovascularización Fishing anti(lymph)angiogenic drugs with zebrafish journal article